SCHEMBL4726732

SCHEMBL4726732

CC(C)CNc1c([N+](=O)[O-])cnc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.45
MAPK1 P28482 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ACP1 P24666 1/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
CHRM3 P20309 1/20 0.41
MAOA P21397 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923304 0.93 MAPT (0.40) MAPTMAPK1TDP1L3MBTL1MEN1
SCHEMBL8120703 0.90 MAPT (0.54) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL6730460 0.87 CHRM2 (0.44) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL10448993 0.85 MAPT (0.41) MAPTMAPK1MEN1KMT2ARAB9A
SCHEMBL9836946 0.85 KMT2A (0.46) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL27365630 0.85 ALDH1A1 (0.41) MAPTMAPK1MEN1KMT2ARAB9A
SCHEMBL4011205 0.84 MEN1 (0.40) MAPTMAPK1TDP1L3MBTL1MEN1
SCHEMBL22749315 0.83 ADRA1A (0.46) MAPTMAPK1TDP1MEN1KMT2A
SCHEMBL22558817 0.83 MAPT (0.44) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL1490815 0.83 MAPT (0.44) MAPTMAPK1TDP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110693850-A Preparation method of imiquimod chitosan nanoparticles 湖北科益药业股份有限公司 2020-01-17 CN claimed
WO-2008023333-A2 PROCESS FOR THE PREPARATION OF 4-(ISOBUTYLAMINO)-3-AMINO-QUINOLINE RANBAXY LABORATORIES LIMITED (US) 2008-02-28 WO claimed
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2025-01-30 US disclosed
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity PHARMA CINQ, LLC (US) 2024-11-12 US disclosed
US-20210163476-A1 IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2021-06-03 US disclosed
US-10934284-B2 Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity WELLSTAT THERAPEUTICS CORPORATION (US) 2021-03-02 US disclosed
CN-108250142-B Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity 维尔斯达医疗公司 2021-01-26 CN disclosed
EP-3632426-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY Wellstat Therapeutics Corporation (US) 2020-04-08 EP disclosed
EP-2950649-B1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY WELLSTAT THERAPEUTICS CORP (US) 2020-03-04 EP disclosed
CN-110693850-A Preparation method of imiquimod chitosan nanoparticles 湖北科益药业股份有限公司 2020-01-17 CN disclosed
US-20190194193-A1 AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY PHARMA CINQ, LLC 2019-06-27 US disclosed
WO-1992015581-A1 PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO disclosed
WO-1992015582-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO disclosed
WO-1992006093-A1 PROCESS FOR THE PREPARATION OF IMIDAZO[4,5-C]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-04-16 WO disclosed
EP-0145340-B1 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1990-01-24 EP disclosed
EP-0326081-A2 Enzyme electrode NEW OJI PAPER CO., LTD. (JP) 1989-08-02 EP disclosed
EP-0310950-A1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1989-04-12 EP disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 US disclosed
EP-0145340-A2 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163476-A1 IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY NOD1, NLRP3, AADAC MAPT 2848/4885MAPK1 814/4885TDP1 3015/4885
US-20190194193-A1 AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY AAAS, AADAC, NFKBIA MAPT 2661/4885MAPK1 862/4885TDP1 2433/4885
US-20250034139-A1 AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY AADAC, CASP1, AAAS MAPT 1131/4885MAPK1 645/4885TDP1 2102/4885
US-12139483-B2 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity NOD1, NLRP3, AADAC MAPT 2848/4885MAPK1 814/4885TDP1 3015/4885
US-10934284-B2 Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity AAAS, AADAC, NFKBIA MAPT 2661/4885MAPK1 862/4885TDP1 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.